Avacopan represents a highly effective and safer option compared to traditional glucocorticoid-based regimens for AAV. The capacity to sustain disease remission with reduced steroid-associated harm highlights its potential utility in evolving vasculitis treatment strategies.
Lee et al. (Tue,) studied this question.